Table 3 Treatment-related adverse events with anlotinib treatment in EGFR negative NSCLC patients
Type | Anlotinib monotherapy (n = 38) | Anlotinib with ICIs (n = 22) | ||
|---|---|---|---|---|
Grade 1–2 | Grade 3–4 | Grade 1–2 | Grade 3–4 | |
Hand-foot syndrome | 16(42.1%) | 2(5.3%) | 13(29.0%) | 2(9.0%) |
Hypertension | 17(44.7%) | 2(5.3%) | 12(54.5%) | 1(4.5%) |
Fatigue | 11(28.9%) | 1(2.6%) | 8(36.4%) | 1(4.5%) |
Diarrhea | 10(26.3%) | 1(2.6%) | 7(31.8%) | 2(9.0%) |
Anorexia | 10(26.3%) | 0 | 6(27.3%) | 0 |
Abnormal liver function | 9(23.7%) | 0 | 6(27.3%) | 0 |
Proteinuria | 9(23.7%) | 2(5.3%) | 5(22.7%) | 1(4.5%) |
Mucositis oral | 7(18.4%) | 1(2.6%) | 3(13.6%) | 1(4.5%) |
Thyroid dysfunction | 6(15.8%) | 0 | 3(13.6%) | 0 |
Arthralgia | 6(15.8%) | 0 | 3(13.6%) | 0 |
Headache | 5(13.2%) | 0 | 2(9.0%) | 0 |